XML 16 R5.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Cash flows from operating activities:    
Net income (loss) $ (3,137,639) $ (6,470,771)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:    
Depreciation and amortization expense 1,394,728 1,314,293
Deferred tax expense 0 4,293,963
Share-based compensation 665,309 551,255
Excess tax (benefit) expense derived from exercise of stock options 0 (91,109)
Noncash interest expense 33,730 51,216
Noncash investment gains (118,188) (18,706)
Net changes in assets and liabilities affecting operating activities:    
Accounts receivable 2,589,017 1,223,213
Inventories (607,653) (182,595)
Other current assets and other assets 804,729 (81,286)
Accounts payable and other current liabilities (730,760) (1,920,653)
Other long-term liabilities 136,402 240,185
Net cash provided by (used in) operating activities 1,029,675 (1,090,995)
Cash flows from investing activities:    
Additions to property and equipment (131,684) (143,150)
Purchases of marketable securities (16,916,890) (1,201,895)
Proceeds from sale of marketable securities 6,904,205 2,486,386
Additions to intangible assets (593,121) (753,900)
Net cash (used in) provided by investing activities (10,737,490) 387,441
Cash flows from financing activities:    
Borrowings on line of credit 24,000,000 6,700,000
Repayments on line of credit (21,800,000) (4,100,000)
Sales of shares of common stock, net of offering costs 200,909 0
Payments of deferred offering costs (248,108) 0
Repurchase of common shares (1,951,199) (1,790,671)
Net cash provided by financing activities 201,602 809,329
Net increase (decrease) in cash and cash equivalents (9,506,213) 105,775
Cash and cash equivalents at beginning of period 45,412,868 34,510,330
Cash and cash equivalents at end of period $ 35,906,655 $ 34,616,105